anti-CD19/BCMA CAR-T cells
- Generic Name
- anti-CD19/BCMA CAR-T cells
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
Early Phase 1
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05302648
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Early Phase 1
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04626752
- Locations
- 🇨🇳
the Second Hospital of HeBei Medical University (HBMU), Shijiazhuang, Hebei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath